Related Experiment Video
Updated: Jul 19, 2026
05:39
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
[BRAF initiating mutations in the papillary thyroid carcinoma]
Dagmara Rusinek1, Elzbieta Gubała
1Department of Nuclear Medicine and Endocrine Oncology MSC Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice. drusinek@io.gliwice.pl
Endokrynologia Polska
|September 29, 2006
Summary
The BRAF gene mutation is the most common genetic driver in papillary thyroid carcinoma (PTC), affecting over half of cases. This mutation is linked to poorer prognosis and distinct gene expression profiles in thyroid cancer.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Context:
- Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer.
- Genetic alterations play a crucial role in the initiation and progression of PTC.
- The BRAF gene mutation (T1799A) is a significant molecular event in PTC.
Purpose:
- To investigate the prevalence and significance of the BRAF gene mutation in papillary thyroid carcinoma.
- To correlate BRAF mutation status with clinicopathological features and patient outcomes.
- To explore the molecular differences associated with BRAF mutation in PTC.
Summary:
- The BRAF T1799A mutation is the most frequent genetic alteration in papillary thyroid carcinoma, occurring in 54.5% of cases across all disease stages.
- BRAF mutation is associated with specific PTC histotypes, particularly the classical and tall cell variants, and is more prevalent in older patients.
- PTC cases with the BRAF V600E mutation exhibit poorer prognosis, increased invasiveness, metastasis, and recurrence, alongside a distinct gene expression signature compared to cases with RET/PTC rearrangements or no known initiating mutation.
Impact:
- Understanding the role of BRAF mutations can aid in risk stratification and personalized treatment strategies for PTC patients.
- Identifying BRAF mutation status may help predict treatment response and patient outcomes.
- This research contributes to the molecular classification of thyroid cancer, guiding future therapeutic development.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...